Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 2, 2025Frontiers in MedicineOpen Access

Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity

View Full Paper
Ask AI
Bookmark
Share

Authors

PWPing Weng

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows blinatumomab combined with chemotherapy improves efficacy and reduces toxicity in newly diagnosed Ph + B-ALL.

Key Points

  • Blinatumomab combined with low-dose chemotherapy improved MRD negativity and reduced relapse rates.
  • The blinatumomab group achieved 90.9% disease-free survival at 12 months, compared to 46.2% in conventional therapy.
  • Patients given blinatumomab experienced shorter neutropenia durations and lower incidence of infections.
  • The safety profile of blinatumomab included fewer transfusions and lower rates of bleeding compared to conventional chemotherapy.

Cite This Study

Ping Weng (2025) studied this question.

synapsesocial.com/papers/692e3d706c9b3ab28c186e66https://doi.org/10.3389/fmed.2025.1687242
View Full Paper
Ask AI
Bookmark
Share